Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
Here's how this drugmaker proved the bears wrong, and why that means it's worth investing $1,500 in today. Read More: Earn up ...
AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades'
AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...
STAT14h
AbbVie’s stumble, Amgen’s tumble, and more election fallout
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
Tremfya's Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights
In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment option. With Johnson & Johnson’s Tremfya now ...
Biohaven Ltd. (BHVN) Receives a Buy from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a ...